

Product Data Sheet

Product Name: PRT-060318 dihydrochloride

Cat. No.: GC81306

Chemical Properties

Cas. No. 3032567-93-1


Formula $C_{18}H_{26}Cl_2N_6O$ M.Wt 413.34

Solubility DMSO: 12.5 mg/mL (30.24 mM); ultrasonic and warming and heat to 60°C) Storage Store at 4°C, away from moisture

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Background

PRT-060318 (PRT318) dihydrochloride is a potent, selective and orally active tyrosine kinase Syk inhibitor with an IC_{50} of 3 nM. PRT-060318 dihydrochloride suppresses chronic lymphocytic leukemia (CLL) B cell activation and migration, and induces apoptosis. PRT-060318 dihydrochloride prevents Heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model. PRT-060318 dihydrochloride can be used for CLL and thrombus research [1] [2].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

In Vivo, PRT-060318 (PRT318) (10 and 30 mg/kg, i.g., b.i.d. for 7 days) dihydrochloride prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model^[1].

In Vitro, PRT-060318 (PRT318) (0-3 μ M, 15 min) dihydrochloride completely inhibits Heparin-induced thrombocytopenia (HIT) immune complex-induced aggregation of both human and transgenic HIT mouse platelets^[1].

References:

- [1]. Reilly MP, et al. PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model. *Blood*. 2011 Feb 17;117(7):2241-6.
- [2]. Hoellenriegel J, et al. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. *Leukemia*. 2012 Jul;26(7):1576-83.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA